Retlirafusp Alfa

Colorectal Cancer

Fudan Universitymonoclonal_antibodyPhase 2/3Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 81/ 100

Competitive context

713 Active assets in the Colorectal Cancer cohort.

Asset / Sponsor	Phase	Rating
Desflurane Peter MacCallum Cancer Centre, Australia	Phase 4	BBB
Marble Dust James Varani	Phase 2/3	BB
Orectalip Sinphar Pharmaceutical Co., Ltd	Phase 4	BB
Fluorouracilum UNICANCER	Phase 4	BB
Levofolinic Acid Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Phase 3	BB

View all 50 →

Same molecule, other indications

Retlirafusp Alfa is also rated in:

non-small cell lung carcinomaActive

BB

Indicative · Phase 3

68 / 100

castration-resistant prostate carcinomaActive

CCC

Indicative · Phase 2

53 / 100

cancerDormant

CCC

Indicative · Phase 1/2

52 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.